title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Funding | Open Access funding enabled and organized by Projekt DEAL. The authors declare that no funds, grants, or other support were received during the preparation of this manuscript. | PMC9970129 | ||
Declarations | PMC9970129 | |||
Disclosure | PD, Sebastián A. | Dr. med. Esther Giehl-Brown, Dr. med. Sandra Dennler, Dr. med. Sebastián A. Garcia, Dr. med. Danilo Seppelt, Dr. med. Florian Oehme, Dr. med. Johannes Schweipert, MHBA, Prof. Dr. med. Jürgen Weitz, MSc and PD Dr. med. Carina Riediger, MSc, have no conflicts of interest or financial ties to disclose. | PMC9970129 | |
References | PMC9970129 | |||
Background | febrile | Parents often contact out-of-hours services due to worry concerning febrile children, despite the children rarely being severely ill. As telephone triage of children is challenging, many children are referred to hospital assessment. This study investigated if video triage resulted in more children staying at home. Seco... | PMC10464404 | |
Methods | death, febrile | In this prospective quality improvement study, nurse call-handlers enrolled febrile children aged 3 months-5 years to video or telephone triage (1:1), with follow-up within 48 h after call. The setting was an out-of-hours call-center for non-urgent illness in Copenhagen, Denmark, receiving over 1 million calls annually... | PMC10464404 | |
Results | There was no difference in triage outcome (home care vs. hospital referral) or number of patients assessed at hospital between triage groups. However, more video triaged patients received in-hospital treatment, testing and hospitalization. | PMC10464404 | ||
Keywords | Open access funding provided by Royal Library, Copenhagen University Library | PMC10464404 | ||
Introduction | ’ worry, febrile, fever | SECONDARY | Telephone triage is used extensively during out-of-hours (OOH) healthcare and is a crucial tool in prioritizing both pre-hospital and in-hospital resources. Telephone triage is a challenging task, and children, the relatively most frequent group of callers, are inherently difficult to triage. This is mainly due to seco... | PMC10464404 |
Methods | PMC10464404 | |||
Setting | injuries | EVENT, EMERGENCY | The study was conducted at the OOH Medical Helpline 1813 (MH1813) in Copenhagen, Denmark, which is open 24/7 for injuries and OOH for medical illness. An assessment at a hospital OOH in Denmark requires referral from either the Emergency Medical Services or an OOH service such as MH1813. Self-referral is largely discou... | PMC10464404 |
Design | fever, ill | A prospective quality improvement study design was used, where a group of experienced nurse call-handlers invited parents of young children to participate. In all calls matching the inclusion criteria and where the parent consented to participation, the call-handlers were instructed to perform standard telephone triage... | PMC10464404 | |
Outcome measures | death | ADVERSE EVENTS, DISEASES, MINOR, ADVERSE EVENT | Outcome data were derived from four sources: MH1813 patient records, questionnaire responses from parents and call-handlers, and the hospitals’ patient charts. The primary outcome of the study was to investigate if video triage could result in 10-percentage points more patients being able to stay at home during the fir... | PMC10464404 |
Statistical analysis | REGRESSION | Patients’ baseline characteristics (age, gender, triage response and symptom) were described with frequency (number, percentage), median and interquartile range (IQR). Differences in triage response, symptoms registered by call-handler and hospital outcome between the video and telephone triage groups were analyzed usi... | PMC10464404 | |
Ethics | EMERGENCY | The study was a quality improvement study, and the Research Ethics Committee in the Capital Region of Denmark deemed approval was not indicated (Journal number H-19037554), and participant consent was hence not needed. All participating parents were however informed about the study and gave verbal consent. The manageme... | PMC10464404 | |
Results | PMC10464404 | |||
Discussion | fever, Non-Danish, ill, worry, tonsillitis | EAR INFECTIONS, MINOR, SECONDARY, TONSILLITIS | Our primary aim was to investigate if video triage could enable more ill children to stay at home, while also efficiently identifying potentially severely ill children with the need for assessment at hospital. There was not a difference in the number of patients triaged to stay at home or in the number of patients asse... | PMC10464404 |
Author contributions | ABH | The study was designed by CG, DC, GL, FF, MSF and ABH. CG conducted the experimental work and collected data. Analysis of data was done by CG, DC, AKE and HGJ. Interpretation of data was conducted by CG, DC, HGJ, GL, ABH, FF and HGJ. CG drafted the initial manuscript. Revising and commenting of manuscript was done by a... | PMC10464404 | |
Funding | Open access funding provided by Royal Library, Copenhagen University Library. The study received unrestricted grants from the TRYG Foundation, the health research foundation of the Capitol Region and the Amager-Hvidovre Hospital research foundation. The funding bodies had no influence on study design or collection, ana... | PMC10464404 | ||
Availability of data and materials | The datasets used during the current study are available from the corresponding author on reasonable request. | PMC10464404 | ||
Declarations | PMC10464404 | |||
Consent for publication | Not applicable. | PMC10464404 | ||
Competing interests | The authors declare that they have no competing interests. | PMC10464404 | ||
References | PMC10464404 | |||
Abstract | PMC9932240 | |||
Objectives | MARF, bone dehiscence, postoperative pain | PERIOSTEUM | One of the simplest methods to increase keratinized gingiva is the modified apically repositioned flap (MARF) technique. In this method, the periosteum remains exposed, which may lead to postoperative pain and discomfort. In the presence of bone dehiscence, bone resorption and gingival recession may occur. Hence, this ... | PMC9932240 |
Material and Methods | MARF | In this randomized controlled trial study, 10 patients (six males and four females with a mean age of 33.9 ± 11.13) with less than 2 mm of attached gingiva bilaterally were treated by the MARF + PRF membrane (test group), on the one hand, whereas, on the other hand, it was treated only by MARF (control group). Clinical... | PMC9932240 | |
Results | MARF | The attached gingival width increased significantly in both groups (1.7 mm in the MARF and 2.3 mm in the PRF) and this was greater in the PRF group ( | PMC9932240 | |
Conclusion | gingiva, MARF, reduced shrinkage, Postoperative pain | Using PRF with the MARF method significantly increased the width and thickness of the gingiva and reduced shrinkage compared to MARF only. Postoperative pain and vestibular depth changes were similar in both groups.
| PMC9932240 | |
INTRODUCTION | gingiva, Gingiva, bone dehiscence, postoperative pain | PERIOSTEUM | Gingiva is the part of oral mucosa that covers the alveolar processes of jaws and surrounds the neck of the teeth. The gingiva is divided anatomically into marginal (unattached), attached, and interdental areas (Newman et al., In this method, a horizontal incision is performed in the attached gingiva and a split‐thickn... | PMC9932240 |
MATERIALS AND METHODS | PMC9932240 | |||
Study design | MARF | This study was designed as a randomized controlled trial with a split‐mouth design. To participate in the study, the following inclusion and exclusion criteria need to be fulfilled. This study was done to evaluate the clinical results of using PRF in combination with MARF to increase the attached gingiva around the tee... | PMC9932240 | |
Inclusion criteria | gingiva | Inclusion criteria in the study were: patients with less than 2 mm of attached gingiva at the buccal site; less than 5 mm of vestibular depth (VD); and the presence of high frenum pull bilaterally in the mandible. | PMC9932240 | |
Exclusion criteria | SYSTEMIC DISEASE, PLAQUE | Exclusion criteria were systemic diseases, pregnancy and lactation, smoking, alcohol use, plaque index >20%, gingival recession Class 3 or 4 Miller, and PPD >5 mm.Patients were invited to participate in the study after being fully informed. Informed consent was obtained from all participants. The study was approved by ... | PMC9932240 | |
Participants and randomization | MARF, Blindness | MAY, BLINDNESS | The present study was performed in the periodontics department of the Dentistry School of Hamadan University of Medical Sciences from May to September 2021; 10 people who had less than 2 mm of attached gingiva and needed soft tissue augmentation on both sides were selected.The sample size was determined based on the as... | PMC9932240 |
Surgical procedures | CAVITY | Chlorhexidine 0.2% was used for rinsing the oral cavity before surgery. Local anesthesia (lidocaine 2% with epinephrine 1:80,000) was performed in the buccal area of the premolars by mental nerve block. | PMC9932240 | |
Control group (MARF) | PERIOSTEUM | A horizontal incision was made by a blade (no. 15) approximately 0.5 mm coronal to the mucogingival junction. The split‐thickness flap was elevated and the dissection was extended 5 mm in an apical direction. The coronal part of the flap would contain a band of keratinized tissue. The extension of the incision depends ... | PMC9932240 | |
Test group (PRF) | MARF | STERILE, PERIOSTEUM | Patient's blood was collected into 10 ml sterile silica‐coated plastic tubes without anticoagulants (VACUETTE; Greiner Bio‐OneOne GmbH, Kremsmünster, Austria). At least two tubes were prepared, and the tubes were centrifuged immediately in a fixed‐angle centrifuge (Arman Teb Noor, Iran, Tabriz). According to studies by... | PMC9932240 |
Primary outcomes: Width and thickness of keratinized tissue | tooth | CAVITY, PERIOSTEUM | The patient's oral cavity was examined by a specialist with Williams Probe (Hu‐Friedy; Chicago, USA) to evaluate the clinical parameters. The evaluated parameters such as probing pocket depth (PPD), keratinized tissue width, VD, and gingival thickness (GT) were measured at the baseline, and after 8 weeks. GT measuremen... | PMC9932240 |
Secondary outcomes: Postoperative pain and wound shrinkage | postoperative pain, pain | SECONDARY | A secondary objective of the study was to assess postoperative pain. A visual analog score (VAS) questionnaire was used to evaluate the amount of pain, ranging from 0 (no pain) to 10 (worst pain), and the patients were asked to fill out the questionnaire on the VAS scales on the day after surgery.To assess the wound sh... | PMC9932240 |
Statistical analysis | The data were checked for normality in distribution using a normal quantile plot. The confidence level was determined at 95%. The patient was used as a statistical unit. After a rejection of normality, a paired | PMC9932240 | ||
RESULT | Postoperative pain, MARF, platelet‐rich, postoperative pain | PERIOSTEUM | Ten patients participated in this trial. The mean age was 33.9 ± 11.1 years old and the male/female ratio was 6:4. None of the subjects dropped out during the 8‐week follow‐up. One side of each patient was randomly assigned to the test (MARF + PRF) or control (MARF) group, while the contralateral side was assigned to t... | PMC9932240 |
DISCUSSION | postoperative pain, Postoperative pain, pain, MARF, bone dehiscence, Inflammation, LSCC | INFLAMMATION, ALMEIDA | A gingival width of 2 mm is sufficient to maintain healthy gingiva (Wennstrom & Lindhe, The apical repositioning flap introduced by Friedman increases the risk of bone resorption (Lang & Löe, In a 1‐ to 11‐year follow‐up study, Carnio et al. (The MARF and PRF groups resulted in a significant increase in keratinized tis... | PMC9932240 |
LIMITATION | Pain | This study was limited to the mandibular premolar area due to the split‐mouth design. Also, a small sample size may be subject to selection bias. Wound shrinkage will continue for months and the complete shrinkage assessed needs long‐term follow‐ups. Pain assessment one day after surgery may lead to bias.To substantiat... | PMC9932240 | |
CONCLUSION | gingiva, MARF, reduced shrinkage, Postoperative pain | DEHISCENCE | Using PRF with the MARF method significantly increased the width and thickness of the gingiva and reduced shrinkage compared to MARF without PRF. Postoperative pain scores and VD changes were similar in the test and control groups. Increasing the GT may allow PRF to be used in the presence of bone dehiscence. | PMC9932240 |
AUTHOR CONTRIBUTIONS | PMC9932240 | |||
CONFLICT OF INTEREST | The authors declare no conflict of interest. | PMC9932240 | ||
ETHICS STATEMENT | The study protocol was registered on the IRCT registry, with Registration reference: IRCT20211124053173N1. | PMC9932240 | ||
ACKNOWLEDGMENTS | The authors would like to thank the dental research center and vice chancellor of research at the Hamadan University of Medical Sciences for their support. This research was fully funded by the research center, Hamadan University of Medical Sciences. | PMC9932240 | ||
DATA AVAILABILITY STATEMENT | The applicant has unlimited access to the data after sending the request via email to the corresponding author. | PMC9932240 | ||
REFERENCES | PMC9932240 | |||
Subject terms | beta-cell dysfunction, diabetes | SECONDARY, INSULIN RESISTANCE, TYPE 2 DIABETES, INSULIN SENSITIVITY, DIABETES | In early type 2 diabetes, the strategy of “induction” with short-term intensive insulin therapy followed by “maintenance” with metformin can stabilize pancreatic beta-cell function in some patients but not others. We thus sought to elucidate determinants of sustained stabilization of beta-cell function. In this seconda... | PMC10374648 |
Introduction | deterioration of pancreatic beta-cell function, T2DM | TYPE 2 DIABETES | The natural history of type 2 diabetes (T2DM) is characterized by the progressive deterioration of pancreatic beta-cell function over timeHere we show that one such strategy is the administration of initial short-term IIT (as induction therapy) followed by metformin (as maintenance therapy), an approach that has been s... | PMC10374648 |
Results | T2DM | The RESET-IT Main trial (ClinicalTrials.Gov NCT02192424) was a multi-centre, parallel arm trial in which adults with T2DM were randomly assigned to receive induction therapy with a 3-week course of IIT, followed by maintenance therapy consisting of either (i) metformin alone or (ii) metformin with intermittent 2-week c... | PMC10374648 | |
Characteristics at Baseline and after 3-weeks Induction | Table Baseline characteristics of study population stratified into (i) participants who had sustained stabilization of beta-cell function for 2 years and (ii) those who did notContinuous variables presented as mean followed by standard deviation in parentheses (if normal distribution) or median followed by interquartil... | PMC10374648 | ||
Characteristics during maintenance phase | adiposity | ADIPOSITY | We next examined the maintenance phase (from 3-weeks to 2-years). Of note, the stabilization and non-stabilization groups did not differ in the maintenance therapy to which participants were randomized (Table Characteristics at completion of maintenance therapy at 2-years in (i) participants who had sustained stabiliza... | PMC10374648 |
Changes over time in metabolic variables. | ( | PMC10374648 | ||
Determinants of sustained beta-cell stabilization | analysesTwo-sided | REGRESSION | Finally, we performed logistic regression analyses to identify independent determinants of the stabilization of beta-cell function at 2-years (Table Logistic regression analyses of (dependent variable) stabilization of beta-cell function over 2 years: (A) core model derivation and (B) sensitivity analysesTwo-sided We n... | PMC10374648 |
Discussion | weight gain, weight loss, T2DM, beta-cell dysfunction | REGRESSION, INSULIN RESISTANCE, INSULIN SENSITIVITY, GESTATIONAL DIABETES | In this study, we show that 55 of 99 patients with T2DM achieved sustained stabilization of beta-cell function over 2-years in response to induction IIT followed by metformin maintenance. These individuals had poorer beta-cell function than their peers at baseline but experienced greater recovery thereof in response to... | PMC10374648 |
Methods | This multi-centre clinical trial was approved by the research ethics boards of Mount Sinai Hospital (Toronto, ON), Western University (London, ON), and Hamilton Health Sciences (Hamilton, ON), which were sites where the study took place. The trial was registered at ClinicalTrials.Gov NCT02192424. It was conducted in ac... | PMC10374648 | ||
Study population | T2DM, liver disease | LIVER DISEASE | Inclusion criteria included age 30–80 years and duration of T2DM ≤ 5 years. Before the trial, participants could be treated with either metformin or lifestyle only. Exclusion criteria included treatment with anti-diabetic medication other than metformin, estimated glomerular filtration rate <50 ml/min, and known liver ... | PMC10374648 |
Randomization and Interventions | Participants stopped metformin (if applicable) and fasted overnight prior to the baseline visit, at which they completed a 2 h 75 g oral glucose tolerance test (OGTT). At this visit, they received instruction on healthy lifestyle practices for managing T2DMThese 2 treatment protocols have been described in detail previ... | PMC10374648 | ||
Physiologic Indices on OGTT | INSULIN SENSITIVITY/RESISTANCE | The serial 2 h 75 g OGTTs enabled assessment of physiologic indices reflecting insulin sensitivity/resistance and beta-cell function. Participants fasted overnight prior to each OGTT, with metformin held on the morning of the test. During each OGTT, venous blood samples were drawn at fasting and at 30-, 60-, 90- and 12... | PMC10374648 | |
Outcomes | SECONDARY | The primary and secondary outcomes of the trial have been previously reported in detail | PMC10374648 | |
Statistical Analyses | Statistical analyses were conducted with R 4.2.2, with two-tailed | PMC10374648 | ||
Reporting summary | Further information on research design is available in the | PMC10374648 | ||
Supplementary information |
Supplementary InformationPeer Review FileReporting Summary | PMC10374648 | ||
Supplementary information | The online version contains supplementary material available at 10.1038/s41467-023-40287-w. | PMC10374648 | ||
Acknowledgements | MOP 133701, Diabetes | GILBERT, DIABETES | RR holds the Boehringer Ingelheim Chair in Beta-cell Preservation, Function and Regeneration at Mount Sinai Hospital. SBH holds the Diabetes Canada Chair in Diabetes Management at Western University. SMR holds the Brian W. Gilbert Chair in Primary Health Care at Western University. HCG holds the McMaster-Sanofi Populat... | PMC10374648 |
Author contributions | R.R. and B.Z. designed the study. R.R., A.E., S.B.H., S.R., H.C.G., N.M., C.K.K. and B.Z. implemented the study and acquired the data. R.R. led overall study implementation. A.E. oversaw research coordination. J.P. performed the statistical analyses. R.R. wrote the manuscript. R.R. and J.P. verified the data. All autho... | PMC10374648 | ||
Peer review | PMC10374648 | |||
Data availability | De-identified data can be made available under restricted access from the corresponding author (Ravi.Retnakaran@SinaiHealth.ca), for academic purposes, subject to a material transfer agreement and approval of the Mount Sinai Hospital Research Ethics Board. Individual participant data that underlie the results reported ... | PMC10374648 | ||
Code availability | The code used for the statistical analyses is available at Github at the following link: | PMC10374648 | ||
Competing interests | N.M., Nordisk | R.R. reports grants from Boehringer Ingelheim, grants and personal fees from Novo Nordisk, personal fees from Sanofi, personal fees from Eli Lilly, outside the submitted work. SBH reports grants and personal fees from Sanofi, grants and personal fees from Novo Nordisk, grants and personal fees from AstraZeneca, persona... | PMC10374648 | |
References | PMC10374648 | |||
Purpose | hematotoxicity | GLIOBLASTOMA | In the randomized phase III trial CeTeG/NOA-09, temozolomide (TMZ)/lomustine (CCNU) combination therapy was superior to TMZ in newly diagnosed MGMT methylated glioblastoma, albeit reporting more frequent hematotoxicity. Here, we analyze high grade hematotoxicity and its prognostic relevance in the trial population. | PMC9886607 |
Methods | hematotoxicity, HAE | ADVERSE EVENTS, ADVERSE EVENT, REGRESSION | Descriptive and comparative analysis of hematotoxicity adverse events ≥ grade 3 (HAE) according to the Common Terminology of Clinical Adverse Events, version 4.0 was performed. The association of HAE with survival was assessed in a landmark analysis. Logistic regression analysis was performed to predict HAE during the ... | PMC9886607 |
Results | HAE | REGRESSION | HAE occurred in 36.4% and 28.6% of patients under CCNU/TMZ and TMZ treatment, respectively. The median onset of the first HAE was during concomitant chemotherapy (i.e. first CCNU/TMZ course or daily TMZ therapy), and 42.9% of patients with HAE receiving further courses experienced repeat HAE. Median HAE duration was si... | PMC9886607 |
Conclusion | HAE | Older age and female sex are associated with higher incidence of HAE. Although occurrence of HAE was not associated with shorter survival, reliable prediction of patients at risk might be beneficial to allow optimal management of therapy and allocation of supportive measures. | PMC9886607 | |
Trial registration | NCT01149109. | PMC9886607 | ||
Keywords | Open Access funding enabled and organized by Projekt DEAL. | PMC9886607 | ||
Introduction | HAE, Glioblastoma, hematologic adverse | GLIOBLASTOMA, PRIMARY BRAIN TUMOR | Glioblastoma is the most common malignant primary brain tumor in adults and has a detrimental prognosis despite standard-of-care treatment with surgery, radiotherapy, and temozolomide chemotherapy [The aim of the present study is to provide a detailed analysis of patterns, predictors and prognostic effect of high grade... | PMC9886607 |
Methods | PMC9886607 | |||
Study design, participants and treatment | HAE, neutropenia, leukopenia, anemia, lymphopenia | ADVERSE EVENT, NEUTROPENIA, THROMBOPENIA, LEUKOPENIA, ADVERSE EVENTS, ANEMIA, LYMPHOPENIA | The CeTeG/NOA-09 study design has been published previously [HAE were defined as thrombopenia, leukopenia, lymphopenia, neutropenia, or anemia of grade 3 or higher. All adverse events were rated according to the Common Terminology of Clinical Adverse Events (CTCAE) version 4.0 and documented using pre-specified clinica... | PMC9886607 |
Statistical analysis | HAE | REGRESSION | Standard descriptive statistics were used for all presented data. Group differences were analyzed with Fisher’s exact test for categorical variables, and Mann-Whitney U test for continuous and ordinal variables as normal distribution could not be assumed.Survival analysis was performed using Cox regression to analyze t... | PMC9886607 |
Results | PMC9886607 | |||
Patterns of hematologic adverse events grade 3 or higher | lymphopenia, HAE, hematotoxicity, neutropenia | ADVERSE EVENTS, NEUTROPENIA, LYMPHOPENIA | The prevalence of HAE was higher in patients treated with CCNU/TMZ compared to treatment with TMZ alone without reaching statistical significance (36.4% (24 of 66) vs. 28.6% (18 of 63), respectively, p = 0.36) as reported before [
Swimmer plot with individual patient data on applied chemotherapy courses and hematotoxi... | PMC9886607 |
Risk of recurring hematotoxicity | HAE | EVENTS | Among patients experiencing HAE, the median number of events was 1 (range, 1–4), with no difference between treatment arms (TMZ: 1 [range 1–4], CCNU/TMZ: 1 [range 1–4], p = 0.40). The risk of repeat HAEs during later courses among patients receiving at least one further course of chemotherapy after first HAE was 42.9% ... | PMC9886607 |
Impact of hematotoxicity on chemotherapy and survival | hematotoxicity, HAE | Chemotherapy was completed (i.e. concomitant + 6 adjuvant courses of TMZ or 6 courses of CCNU/TMZ) in 40.6% (26 of 66) of patients receiving CCNU/TMZ and 59.4% (38 of 63) of patients receiving TMZ, as reported before [According to protocol, chemotherapy was stopped if a course was delayed by more than 6 weeks. More pat... | PMC9886607 | |
Discussion | HAE, hematologic adverse, toxicity, lymphopenia, glioma, hematotoxic, hematotoxicity | LYMPHOPENIA, EVENTS, GLIOMA | The present study provides a detailed comparative analysis of high grade hematotoxicity in the CeTeG/NOA-09 trial. No hematologic adverse event grade 5 was reported and the overall frequency of HAE showed a non-significant tendency to be higher with CCNU/TMZ as compared to TMZ [HAE patterns differed between the treatme... | PMC9886607 |
Author contribution | JW, CS and UH designed the analysis. JW performed data analysis and wrote the first draft of the manuscript. CS and UH supervised the work. All authors contributed to data acquisition, commented on previous versions and read and approved the final manuscript. | PMC9886607 | ||
Funding | Open Access funding enabled and organized by Projekt DEAL. The trial was funded by the German Ministry for Education and Science (Grant No. 01KG1005). | PMC9886607 | ||
Data availability | The dataset is available from the corresponding author upon reasonable request. The data are not publicly available due to privacy restrictions. | PMC9886607 | ||
Declarations | PMC9886607 | |||
Conflict of interest | Janssen-Cillag, Novocure | UH has received lecture and/or advisory board honoraria from Medac, Novartis, Daichii-Sankyo, Noxxon, AbbVie, Bayer, Janssen, and Karyopharm. CS has received lecture or advisory board honoraria from AbbVie, Bristol-Myers Squibb, HRA Pharma, Medac, Roche, and Seagen. GT has received lecture, consultant or advisory board... | PMC9886607 | |
Informed to consent | All procedures performed in studies involving human participants were in accordance with the ethical standards of the Helsinki Declaration and its later amendments and the Guidelines for Good Clinical Practice. The study was approved by the Ethics committees of all participating centers.Written informed consent was obt... | PMC9886607 | ||
References | PMC9886607 | |||
1. Introduction | OA, inflammation, osteoarthritis, arthritis, pain, joints | RHEUMATOID ARTHRITIS, INFLAMMATION, JOINT DISEASES, OSTEOARTHRITIS, ARTHRITIS, DISEASES | Methylsulfonylmethane (MSM) is a food ingredient present in small amounts in many foods, and its anti-inflammatory effects have been reported. We conducted a randomized, double-blind, placebo-controlled trial of oral consumption of MSM on mild pain of the knee joint in healthy Japanese participants. A total of 88 parti... | PMC10346176 |
2. Materials and Methods | PMC10346176 | |||
2.1. Study Aim | knee pain | This study aimed to determine the effect of oral consumption of MSM on knee joint quality of life (QOL) in mild knee pain participants. | PMC10346176 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.